Inger Sandlie

List of Publications by Year
in descending order

121 papers	5,872 citations	71102 41 h-index	82547 72 g-index
126 all docs	126 docs citations	126 times ranked	6201 citing authors

#	Article	IF	Citations
1	Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews Drug Discovery, 2003, 2, 52-62.	46.4	468
2	The Neonatal Fc Receptor (FcRn): A Misnomer?. Frontiers in Immunology, 2019, 10, 1540.	4.8	271
3	Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Communications, 2011, 2, 599.	12.8	220
4	Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Frontiers in Immunology, 2014, 5, 682.	4.8	188
5	Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8^{âˆ’}CD11b⁺dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9927-9932.	7.1	187
6	Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding. Journal of Biological Chemistry, 2010, 285, 4826-4836.	3.4	165
7	Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nature Communications, 2012, 3, 610.	12.8	160
8	The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. Journal of Controlled Release, 2015, 211, 144-162.	9.9	152
9	Aglycosylated IgG variants expressed in bacteria that selectively bind FcÎ³RI potentiate tumor cell killing by monocyte-dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 604-609.	7.1	146
10	The structural requirements for complement activation by IgG: does it hinge on the hinge?. Trends in Immunology, 1995, 16, 85-90.	7.5	140
11	Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies. Nature Nanotechnology, 2019, 14, 184-190.	31.5	134
12	Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding. Journal of Biological Chemistry, 2014, 289, 13492-13502.	3.4	132
13	Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. Journal of Immunological Methods, 1997, 204, 77-87.	1.4	121
14	The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. European Journal of Immunology, 2006, 36, 3044-3051.	2.9	108
15	The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics. Drug Metabolism and Pharmacokinetics, 2009, 24, 318-332.	2.2	107
16	Posttranslational Modification of Gluten Shapes TCR Usage in Celiac Disease. Journal of Immunology, 2011, 187, 3064-3071.	0.8	92
17	Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology, 2015, 220, 452-459.	1.9	90
18	Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Molecular Immunology, 2000, 37, 995-1004.	2.2	85

#	Article	IF	Citations
19	TRIM21â€"From Intracellular Immunity to Therapy. Frontiers in Immunology, 2019, 10, 2049.	4.8	85
20	Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2862-E2871.	7.1	84
21	<scp>TRIM</scp>21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunological Reviews, 2015, 268, 328-339.	6.0	78
22	Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. Journal of Immunological Methods, 2005, 298, 93-104.	1.4	76
23	DNA Vaccines Increase Immunogenicity of Idiotypic Tumor Antigen by Targeting Novel Fusion Proteins to Antigen-Presenting Cells. Molecular Therapy, 2006, 13, 776-785.	8.2	68
24	Polymeric human Fc-fusion proteins with modified effector functions. Scientific Reports, 2011, 1, 124.	3.3	68
25	Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Molecular Immunology, 1992, 29, 319-326.	2.2	64
26	Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation. Molecular Therapy, 2004, 9, 328-336.	8.2	63
27	Structural requirements for the interaction of human IgM and IgA with the human FcÎ±/Î¼ receptor. European Journal of Immunology, 2009, 39, 1147-1156.	2.9	63
28	Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcÎ³RIIa Affinity and Selectivity. ACS Chemical Biology, 2013, 8, 368-375.	3.4	61
29	Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues FromÂPatients With Celiac Disease. Gastroenterology, 2019, 156, 1428-1439.e10.	1.3	61
30	Solution Conformation of Wild-Type and Mutant IgG3 and IgG4 Immunoglobulins Using Crystallohydrodynamics: Possible Implications for Complement Activation. Biophysical Journal, 2007, 93, 3733-3744.	0.5	59
31	A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nature Communications, 2018, 9, 621.	12.8	59
32	The Carboxyl-terminal Domains of IgA and IgM Direct Isotype-specific Polymerization and Interaction with the Polymeric Immunoglobulin Receptor. Journal of Biological Chemistry, 2002, 277, 42755-42762.	3.4	58
33	Structural requirements for incorporation of J chain into human IgM and IgA. International Immunology, 2000, 12, 19-27.	4.0	56
34	Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. Journal of Immunology, 2015, 194, 5497-5508.	0.8	56
35	Identification of Residues in the CÎ¼4 Domain of Polymeric IgM Essential for Interaction with<i>Plasmodium falciparum</i>Erythrocyte Membrane Protein 1 (PfEMP1). Journal of Immunology, 2008, 181, 1988-2000.	0.8	55
36	Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner. Journal of Biological Chemistry, 2013, 288, 24277-24285.	3.4	55

#	Article	IF	Citations
37	Complement C4 Prevents Viral Infection through Capsid Inactivation. Cell Host and Microbe, 2019, 25, 617-629.e7.	11.0	53
38	Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nature Biotechnology, 1999, 17, 670-675.	17.5	51
39	Differential Segmental Flexibility and Reach Dictate the Antigen Binding Mode of Chimeric IgD and IgM: Implications for the Function of the B Cell Receptor. Journal of Immunology, 2004, 172, 2925-2934.	0.8	45
40	Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood, 2013, 122, 1174-1181.	1.4	43
41	Human and mouse albumin bind their respective neonatal Fc receptors differently. Scientific Reports, 2018, 8, 14648.	3.3	42
42	Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin. European Journal of Immunology, 1999, 29, 1701-1708.	2.9	41
43	Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. European Journal of Immunology, 1994, 24, 2542-2547.	2.9	40
44	The influence of the hinge region length in binding of human IgG to human FcÎ³ receptors. Human Immunology, 1998, 59, 720-727.	2.4	40
45	An intact C-terminal end of albumin is required for its long half-life in humans. Communications Biology, 2020, 3, 181.	4.4	40
46	The effect of caffeine on cell growth and metabolism of thymidine in Escherichia coli. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1980, 73, 29-41.	1.0	39
47	Activation of complement by an IgG molecule without a genetic hinge. Nature, 1993, 363, 628-630.	27.8	39
48	Efficient Delivery of T Cell Epitopes to APC by Use of MHC Class II-Specific Troybodies. Journal of Immunology, 2002, 168, 2154-2162.	0.8	38
49	Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies. Journal of Biological Chemistry, 2014, 289, 17228-17239.	3.4	38
50	T Cell Recognition of the Dominant I-Akâ€"Restricted Hen Egg Lysozyme Epitope. Journal of Experimental Medicine, 2001, 193, 1239-1246.	8.5	37
51	An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Science Translational Medicine, 2020, 12, .	12.4	37
52	C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids. European Journal of Immunology, 1989, 19, 1599-1603.	2.9	36
53	Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn). Journal of Biological Chemistry, 2014, 289, 34583-34594.	3.4	36
54	Targeting the MHC Ligandome by Use of TCR-Like Antibodies. Antibodies, 2019, 8, 32.	2.5	36

#	Article	IF	Citations
55	Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation. Journal of Immunology, 2013, 191, 4769-4777.	0.8	34
56	TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity. Journal of Immunology, 2016, 196, 3452-3459.	0.8	34
57	Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications. Scientific Reports, 2015, 5, 9526.	3.3	33
58	Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hing. European Journal of Immunology, 1991, 21, 2379-2384.	2.9	31
59	Immunoglobulin as a vehicle for foreign antigenic peptides immunogenic to T cells. Molecular Immunology, 1997, 34, 1167-1176.	2.2	31
60	Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS Journal, 2008, 275, 4097-4110.	4.7	30
61	Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life. Journal of Biological Chemistry, 2012, 287, 22927-22937.	3.4	30
62	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Engineering, Design and Selection, 2013, 26, 187-193.	2.1	30
63	Expanding the Versatility of Phage Display II: Improved Affinity Selection of Folded Domains on Protein VII and IX of the Filamentous Phage. PLoS ONE, 2011, 6, e17433.	2.5	30
64	FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Clinical Biochemistry, 2010, 43, 367-372.	1.9	29
65	A strategy for bacterial production of a soluble functional human neonatal Fc receptor. Journal of Immunological Methods, 2008, 331, 39-49.	1.4	28
66	Next generation phage display by use of pVII and pIX as display scaffolds. Methods, 2012, 58, 40-46.	3.8	28
67	Antibody-antigen kinetics constrain intracellular humoral immunity. Scientific Reports, 2016, 6, 37457.	3.3	27
68	Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. Journal of Controlled Release, 2016, 223, 42-52.	9.9	25
69	FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complexâ€“driven autoimmunity. Journal of Experimental Medicine, 2020, 217, .	8.5	24
70	Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Frontiers in Oncology, 2012, 2, 154.	2.8	23
71	Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Scientific Reports, 2013, 3, 1162.	3.3	23
72	Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. IScience, 2022, 25, 103746.	4.1	23

#	Article	IF	Citations
73	Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnology, 2010, 10, 8.	3.3	22
74	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nuclear Medicine and Biology, 1995, 22, 765-771.	0.6	21
75	Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation. Journal of Immunological Methods, 2000, 245, 119-131.	1.4	20
76	Expanding the Versatility of Phage Display I: Efficient Display of Peptide-Tags on Protein VII of the Filamentous Phage. PLoS ONE, 2011, 6, e14702.	2.5	20
77	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Immunotechnology: an International Journal of Immunological Engineering, 1998, 4, 141-153.	2.4	19
78	Abundant Tyrosine Residues in the Antigen Binding Site in Anti-Osteosarcoma Monoclonal Antibodies Tp-1 and Tp-3: Application to radiolabeling. Acta OncolÃ³gica, 1996, 35, 297-301.	1.8	16
79	Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activationin vitro. European Journal of Immunology, 2001, 31, 94-106.	2.9	16
80	Reliable titration of filamentous bacteriophages independent of pIII fusion moiety and genome size by using trypsin to restore wild-type pIII phenotype. BioTechniques, 2008, 44, 551-554.	1.8	16
81	Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn<i>in vitro</i>and<i>in vivo</i>. MAbs, 2021, 13, 1893888.	5.2	16
82	The extended hinge region of IgG3 is not required for high phagocytic capacity mediated by FcÎ³ receptors, but the heavy chains must be disulfide bonded. European Journal of Immunology, 1993, 23, 1546-1551.	2.9	15
83	A high-affinity human TCR-like antibody detects celiac disease gluten peptideâ€“MHC complexes and inhibits T cell activation. Science Immunology, 2021, 6, .	11.9	15
84	A TCRÎ± frameworkâ€“centered codon shapes a biased T cell repertoire through direct MHC and CDR3Î² interactions. JCI Insight, 2017, 2, .	5.0	15
85	Identification of a Polymeric Ig Receptor Binding Phage-displayed Peptide That Exploits Epithelial Transcytosis without Dimeric IgA Competition. Journal of Biological Chemistry, 2006, 281, 7075-7081.	3.4	14
86	A Receptor-Mediated Mechanism to Support Clinical Observation of Altered Albumin Variants. Clinical Chemistry, 2007, 53, 2216-2216.	3.2	14
87	Functional in vitro studies of recombinant human immunoglobulinâ€ƒG and immunoglobulinâ€ƒA anti-D. Transfusion, 2007, 47, 306-315.	1.6	14
88	Multivalent pIX phage display selects for distinct and improved antibody properties. Scientific Reports, 2016, 6, 39066.	3.3	14
89	Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge. Science Immunology, 2022, 7, eabj1640.	11.9	14
90	Mechanism of inhibition of thymidine kinase fromEscherichia coliby caffeine. FEBS Letters, 1980, 110, 223-226.	2.8	13

#	Article	IF	Citations
91	Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Molecular Immunology, 2002, 38, 833-840.	2.2	13
92	In vitro assessment of recombinant, mutant immunoglobulinâ€ƒG antiâ€Ð devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. Transfusion, 2008, 48, 12-19.	1.6	13
93	DeltaPhageâ€"a novel helper phage for high-valence pIX phagemid display. Nucleic Acids Research, 2012, 40, e120-e120.	14.5	13
94	Animal models for evaluation of albumin-based therapeutics. Current Opinion in Chemical Engineering, 2018, 19, 68-76.	7.8	13
95	Soluble T-cell receptor design influences functional yield in an E. coli chaperone-assisted expression system. PLoS ONE, 2018, 13, e0195868.	2.5	13
96	A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. European Journal of Immunology, 2006, 36, 129-138.	2.9	11
97	Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis. Molecular Immunology, 1993, 30, 1419-1425.	2.2	9
98	Selection of Nanobodies that Target Human Neonatal Fc Receptor. Scientific Reports, 2013, 3, 1118.	3.3	9
99	â€˜Troy-bodiesâ€™: antibodies as vector proteins for T cell epitopes. New Biotechnology, 2001, 18, 109-116.	2.7	8
100	Identification of a High Affinity FcÎ³RIIA-binding Peptide That Distinguishes FcÎ³RIIA from FcÎ³RIIB and Exploits FcÎ³RIIA-mediated Phagocytosis and Degradation. Journal of Biological Chemistry, 2009, 284, 1126-1135.	3.4	8
101	Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins. BMC Biotechnology, 2010, 10, 61.	3.3	8
102	The neonatal Fc receptor in mucosal immune regulation. Scandinavian Journal of Immunology, 2021, 93, e13017.	2.7	8
103	Induction of central T cell tolerance: Recombinant antibodies deliver peptides for deletion of antigen-specific CD4+8+ thymocytes. European Journal of Immunology, 2005, 35, 3142-3152.	2.9	7
104	Mechanism of caffeine-induced inhibition of DNA synthesis inEscherichia coli. FEBS Letters, 1983, 151, 237-242.	2.8	6
105	Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunology, Immunotherapy, 1999, 48, 411-418.	4.2	6
106	Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes. Journal of Leukocyte Biology, 2005, 77, 303-310.	3.3	6
107	Processing of an Antigenic Sequence from IgG Constant Domains for Presentation by MHC Class II. Journal of Immunology, 2008, 181, 7062-7072.	0.8	6
108	In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells. Apmis, 2006, 114, 345-351.	2.0	5

#	Article	IF	Citations
109	Recombinant antibodies for delivery of antigen: a single loop between Â-strands in the constant region can accommodate long, complex and tandem T cell epitopes. International Immunology, 2008, 20, 295-306.	4.0	4
110	Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor PeptideÃ¢â‚¬â€œMHC Interactions. Frontiers in Oncology, 2015, 4, 378.	2.8	4
111	Effect of caffeine on nucleotide pools in Escherichia coli. Chemico-Biological Interactions, 1982, 40, 141-148.	4.0	3
112	â€œTroy-bodiesâ€ Recombinant Antibodies that Target T Cell Epitopes to Antigen Presenting Cells. International Reviews of Immunology, 2001, 20, 647-673.	3.3	3
113	CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses. Protein Engineering, Design and Selection, 2012, 25, 89-96.	2.1	3
114	A <i>TRAV26â€1</i>â€encoded recognition motif focuses the biased T cell response in celiac disease. European Journal of Immunology, 2020, 50, 142-145.	2.9	2
115	Engineering of the Fc Region for Improved PK (FcRn Interaction). , 2010, , 411-430.		2
116	Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin. , 1999, 29, 1701.		1
117	The Influence of FcRn on Albumin-Fused and Targeted Drugs. , 2016, , 179-208.		1
118	Balanced expression of single subunits in a multisubunit protein, achieved by cell fusion of individual transfectants. FEBS Journal, 2002, 269, 3205-3210.	0.2	0
119	Extending Antibody Fragment Half-Lives with Albumin. , 0, , 293-310.		0
120	Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses. Vaccine, 2021, 39, 1583-1592.	3.8	0
121	Phage Display and Selection of Protein Ligands. , 2015, , 115-134.		0